Menu
Back to User profile » Dr Lene Hammer-Helmich
Papers published by Dr Lene Hammer-Helmich:
Effectiveness and Safety of Vortioxetine for Major Depressive Disorder in Real-World Clinical Practice: Results from the Single-Arm RELIEVE China Study
Wang G, Xiao L, Ren H, Simonsen K, Ma J, Xu X, Guo P, Wang Z, Bai L, Heldbo Reines E, Hammer-Helmich L
Neuropsychiatric Disease and Treatment 2022, 18:1939-1950
Published Date: 30 August 2022
Relationship of Subjective Cognitive Impairment with Psychosocial Function and Relapse of Depressive Symptoms in Patients with Major Depressive Disorder: Analysis of Longitudinal Data from PERFORM-J
Sumiyoshi T, Watanabe K, Noto S, Sakamoto S, Moriguchi Y, Hammer-Helmich L, Fernandez J
Neuropsychiatric Disease and Treatment 2021, 17:945-955
Published Date: 26 March 2021
Impact of Cognitive Symptoms on Health-Related Quality of Life and Work Productivity in Chinese Patients with Major Depressive Disorder: Results from the PROACT Study
Wang G, Tan KHX, Ren H, Hammer-Helmich L
Neuropsychiatric Disease and Treatment 2020, 16:749-759
Published Date: 13 March 2020
Patient-reported depression severity and cognitive symptoms as determinants of functioning in patients with major depressive disorder: a secondary analysis of the 2-year prospective PERFORM study
Haro JM, Hammer-Helmich L, Saragoussi D, Ettrup A, Larsen KG
Neuropsychiatric Disease and Treatment 2019, 15:2313-2323
Published Date: 13 August 2019
Long-term follow-up on health-related quality of life in major depressive disorder: a 2-year European cohort study
Saragoussi D, Christensen MC, Hammer-Helmich L, Rive B, Touya M, Haro JM
Neuropsychiatric Disease and Treatment 2018, 14:1339-1350
Published Date: 22 May 2018
Functional impairment in patients with major depressive disorder: the 2-year PERFORM study
Hammer-Helmich L, Haro JM, Jönsson B, Tanguy Melac A, Di Nicola S, Chollet J, Milea D, Rive B, Saragoussi D
Neuropsychiatric Disease and Treatment 2018, 14:239-249
Published Date: 9 January 2018